Glimfal 2mg/500mg Tablet SR is a combination oral antihyperglycemic agent containing Glimepiride 2mg and Metformin 500mg in a sustained-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea, acts by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The sustained-release formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Glimfal should be used as part of a comprehensive diabetes management plan, including diet and exercise, under medical supervision. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Dose adjustments may be necessary based on therapeutic response and tolerability. Glimfal is not intended for the treatment of diabetic ketoacidosis or type 1 diabetes mellitus.